Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses various techniques for evaluating hair shedding and alopecia but reports no new clinical results. The authors emphasize the value of specific clinical and instrumental methods in assessing hair growth.

This study quantified hair shedding in women without female pattern hair loss and found that about 40% experienced excessive shedding during hair washing, emphasizing the need for further research into this common concern.

This study reported that once-daily treatment with oral minoxidil and spironolactone for 12 months reduced hair loss severity and hair shedding in women with pattern hair loss, with generally mild side effects, though results came from an uncontrolled, observational pilot study.

This study found that a combination of 5% hexane extract of Curcuma aeruginosa and 5% minoxidil slowed hair loss and increased hair growth in men with androgenetic alopecia.

This article discusses hair shedding in women and does not offer new research results; it highlights the need for objective criteria to define excessive hair shedding.

This article introduces a new grading system called the FPHL Severity Index to better identify and monitor early stages of female pattern hair loss using clinical criteria.

This study established and validated a visual scale to assess hair shedding in women with thick hair, finding it effective in distinguishing greater hair loss among women with female pattern hair loss compared to those without.

This article discusses the potential of oral bicalutamide as a promising treatment for female pattern hair loss and reports no new clinical results.

This article reviews the use of various treatments for alopecia and their potential impact on COVID-19 outcomes, emphasizing the importance of patient registries in generating real-world evidence; it reports no new results.

In this report, a 44-year-old woman with female pattern alopecia experienced significant hair regrowth after 3.5 months of oral finasteride, with no side effects, after not responding to topical minoxidil.

PRP treatment satisfies 58% of female hair loss patients, with most noticing fuller, thicker hair and less shedding.

This study found that 1 mg/day low-dose oral minoxidil significantly increased hair count compared to 0.25 mg/day over 24 weeks in women with female pattern hair loss, though no differences were observed in hair-shedding and quality-of-life scores between the two doses.

In this study, Spectral DNC-N® significantly reduced hair shedding and increased hair mass and density in women with early female pattern hair loss, with effects evident after 3 months and sustained through 6 months.

This study in Chinese patients with male pattern baldness found that 2% minoxidil solution led to moderate hair growth in 22% of participants and was generally well-tolerated.

2% topical minoxidil can help reduce hair loss and promote hair growth in male pattern baldness.

In this study, trichoscopy was found to enhance the early assessment of minoxidil therapy in males with pattern hair loss, leading to improved satisfaction and treatment compliance by revealing positive changes visible within one month.

Bicalutamide may reduce hair shedding in women but needs longer trials to confirm its effectiveness.

This randomized, controlled clinical trial found that combining 25 mg/d bicalutamide with 1 mg/d minoxidil for 24 weeks did not enhance hair density improvement in female pattern hair loss compared to 1 mg/d minoxidil alone, with no significant difference observed between the groups.

Most women continued using oral minoxidil for hair loss despite mild to moderate side effects.

This study found that three sessions of injectable platelet-rich fibrin (i-PRF+) significantly improved hair follicle density, hair volume, and thickness, as well as patient satisfaction in women with female pattern hair loss, with only minor self-limited adverse effects reported.

This study developed and validated the Hair-Shedding Visual Scale for Asian Women, finding it to be an effective tool for identifying FPHL and TE.

In this study conducted at a Pakistani hospital, skin diseases accounted for 5.5% of outpatient cases, with infections, scabies, and eczema being the most common conditions observed.

In this study, 24 weeks of using Scalpoo® shampoo, containing ingredients like biotin and herbal compounds, significantly reduced hair shedding by 43.6% and increased hair thickness and count in patients with male and female pattern hair loss, as assessed by imaging and expert evaluations.

This study found that the ENERGI-F701 solution significantly increased hair density and reduced hair shedding in women with female pattern hair loss, with fewer local skin reactions compared to Regaine® 2% minoxidil, suggesting its effectiveness and safety as a treatment option.

This study suggests that using a non-medicated, hypo-allergenic scalp clarifying shampoo may improve hair volume and reduce shedding in women with lichen planopilaris and female pattern hair loss.

This study concluded that intralesional lyophilized growth factor injections are safe and improve trichoscopic hair parameters and clinical scores in patients with female pattern hair loss.

In this hospital-based observational study involving 30 participants, researchers found no statistically significant difference in the force needed to pluck anagen versus telogen hair in the frontal and occipital scalp regions of women with female pattern hair loss.

In this study, trichoscopy was found to be an effective noninvasive tool for diagnosing female pattern hair loss at early stages, potentially eliminating the need for scalp biopsies.

This abstract discusses platelet-rich plasma therapy for patterned hair loss but provides no new clinical results, suggesting further research is needed to determine its effectiveness.

This study observed that the COVID-19 pandemic altered the pattern of dermatoses among Iraqi females, with significant increases in hair loss and decreases in viral skin infections.